SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Roscoe JA, Morrow GR, Hickok JT, Stern RM. Nausea and vomiting remain a significant clinical problem: trends over time in controlling chemotherapy-induced nausea and vomiting in 1413 patients treated in community clinical practices. J Pain Symptom Manage. 2000; 20: 113121.
  • 2
    Griffin AM, Butow PN, Coates AS, et al. On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol. 1996; 7: 189195.
  • 3
    Sun CC, Bodurka DC, Weaver CB, et al. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer. 2005; 13: 219227.
  • 4
    Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999; 17: 29712994.
  • 5
    Roila F, Hesketh PJ, Herrstedt J, Antiemetic Subcommittee of the Multinational Association of Supportive Care in C. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006; 17: 2028.
  • 6
    MASCC. Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol. 1998; 9: 811819.
  • 7
    Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003; 98: 24732482.
  • 8
    Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003; 14: 15701577.
  • 9
    Grunberg SM, Koeller JM. Palonosetron: a unique 5-HT3-receptor antagonist for the prevention of chemotherapy-induced emesis. Expert Opin Pharmacother. 2003; 4: 22972303.
  • 10
    Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003; 21: 41124119.
  • 11
    Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003; 97: 30903098.
  • 12
    National Comprehensive Cancer Network. Antiemesis: clinical practice guidelines in oncology v1. 2005. Available at URL: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf Accessed on January 2, 2006.
  • 13
    Roila F, Hesketh PJ, Herrstedt J. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006; 17: 2028.
  • 14
    Stewart DJ, Dahrouge S, Coyle D, Evans WK. Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy. J Clin Oncol. 1999; 17: 344351.
  • 15
    Ihbe-Heffinger A, Ehlken B, Bernard R, et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann Oncol. 2004; 15: 526536.
  • 16
    Vanscoy GJ FB, Smith R, Weber R, Rihn TL. Preventing chemotherapy-induced nausea and vomiting: the economic implications of choosing antiemetics. Commun Oncol. 2005; 2: 127132.
  • 17
    Kwong WJ, Parasuraman TV. Cost-effectiveness analysis of oral ondansetron and prochlorperazine for preventing nausea and vomiting after moderately emetogenic chemotherapy. Pharm Pract Manag Q. 1999; 19: 2841.
  • 18
    Lachaine J, Laurier C. Cost-efficacy analysis of ondansetron regimens for control of emesis induced by noncisplatin, moderately emetogenic chemotherapy. Am J Health Syst Pharm. 2002; 59: 18371846.
  • 19
    Sanchez LA, Holdsworth M, Bartel SB. Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implications. Pharmacoeconomics. 2000; 18: 533556.
  • 20
    Thomas Medstat. 1997–2002 MarketScan Health and Productivity Management Database User Guide and Data Dictionary. Ann Arbor, MI: Thomas Medstat; 2003.
  • 21
    MASCC. Antiemetic Guidelines, vol. 2007. Perugia, 2005. Available at URL: http://www.mascc.org/media/Resource_centers/MASCC_Guidelines_Update_9_05.pdf Accessed on February 27, 2007.
  • 22
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373383.
  • 23
    Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 12581267.
  • 24
    Duan N. Smearing estimate: a nonparametric retransformation method. J Am Stat Assoc. 1983; 78: 605610.
  • 25
    Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998; 17: 283295.
  • 26
    Bureau of Labor Statistics. National Compensation Survey: Occupational Wages in the United States, 1997–2002. Available at URL: http://www.bls.gov/ncs/ncspubs.htm#Compensation Accessed on December 22, 2005.
  • 27
    Bureau of Labor Statistics. Consumer Price Index — Urban Wage Earners and Clerical Workers. Available at URL: http://data.bls.gov/cgi-bin/surveymost Accessed on December 22, 2005.
  • 28
    Halvorsen R, Palmquist R. The interpretation of dummy variables in semilogarithmic equations. Am Econ Rev. 1980; 70: 474475.
  • 29
    Gralla RJ. New agents, new treatment, and antiemetic therapy. Semin Oncol. 2002; 29(1 Suppl 4 ): 119124.
  • 30
    Kris MG. Why do we need another antiemetic? Just ask. J Clin Oncol. 2003; 21: 40774080.
  • 31
    Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004; 100: 22612268.
  • 32
    Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985; 3: 13791384.
  • 33
    Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005; 23: 12891294.